HC Wainwright Has Pessimistic Outlook of SLN FY2024 Earnings
Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Silence Therapeutics in a report issued on ...
What is HC Wainwright’s Forecast for BTAI FY2024 Earnings?
Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...
Hosted on MSN15h
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy Recommendation
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
H.C. Wainwright Raises BlackSky Technology Inc. (BKSY) Price Target to $20, Maintains ‘Buy’ Amid Strong Contract Growth
We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...
bovnews18h
The BBAI Conundrum: Why BigBear.ai Holdings Inc’s Stock Is Making Headlines Again
H.C. Wainwright has recently reiterated BigBear.ai Holdings Inc (BBAI) stock to Buy rating, as announced on December 30, 2024, according to Finviz. Earlier, on January 9, 2024, Cantor Fitzgerald had ...
Knightscope, Inc. (KSCP) Receives ‘Buy’ Rating from H.C. Wainwright with $16 Target
We recently compiled a list of the 10 Trending AI Stocks on Wall Street’s Radar. In this article, we are going to take a look ...
Xoma price target lowered to $104 from $123 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed ...
BlackSky price target raised to $20 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BlackSky (BKSY) to $20 from $12 and keeps a Buy rating on the shares. The firm says that as ...
TMCnet3d
H.C. Wainwright Initiates Coverage on Knightscope (NASDAQ: KSCP) with a Buy Rating and $16 Price Target
Knightscope, Inc. (NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has initiated coverage on the ...
Investing17d
H.C. Wainwright maintains buy on Akero stock
On Friday, H.C. Wainwright reaffirmed its Buy rating and $50.00 price target for Akero Therapeutics (NASDAQ:AKRO), representing significant upside potential from the current trading price of $24.01.
Investing18d
H.C. Wainwright sets target on Aprea stock, Buy rating on clinical update
On Thursday, H.C. Wainwright reaffirmed its Buy rating and $20.00 stock price target for Aprea Therapeutics (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel ...